墨西哥跨性别女性填充剂相关并发症的流行病学与临床结局
Epidemiology and clinical outcomes of filler-related complications among transgender women in Mexico
一项在墨西哥城三家公立转诊中心开展的回顾性研究显示,222名有填充剂注射史的跨性别女性中,44.5%出现填充剂相关并发症,多为炎症或混合表现。在信息可获得者中,93%的注射由非医疗人员实施;54%的并发症从注射到症状出现超过5年,超过三分之一的受影响者因此住院。
- Article
- Open access
- Published: 14 October 2026
- Karen Aranza Marañón-Solorio ORCID: orcid.org/0009-0006-7072-45161,
- Mariana Vélez-Pintado ORCID: orcid.org/0000-0002-7834-49172,
- América Sarahí Martínez-Frías2,
- Esmeralda Román-Mar2,
- Mitzi Zaira Fong-Ponce2,
- Montserrat Staeps-Gordoa2,
- Juanita Lastra-Torres2,
- Elizabeth Vancini-Nieto3,
- María Eugenia Zghaib-Rivero2,
- Paula Viveros-Wacher4,
- Alvaro López-Iñiguez ORCID: orcid.org/0000-0001-7128-22421,
- Alfredo Ponce-de-León ORCID: orcid.org/0000-0003-2640-29161 &
- …
- Fernanda González-Lara ORCID: orcid.org/0000-0003-0292-34421,5
Scientific Reports (2026) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
Filler-related complications (FRC) arise from the injection of high-density substances used to modify the body in order to harmonize gender identity and/or gender expression and represent an emerging public health problem. Among transgender women, limited access to gender-affirming healthcare, together with other psychosocial, structural, and social factors, may contribute to the use of body modification practices intended to harmonize gender identity and gender expression, including the use of injectable materials. We conducted a retrospective analytical study among transgender women with a history of filler injections receiving care at three public referral centers in Mexico City between September 2024 and July 2025. Participants were identified through review of available clinical records and transgender care registries. Transgender identity was determined based on self-identified gender documented in the clinical record and confirmed through clinical chart review. Demographic, clinical, and social variables were collected to characterize FRC and associated factors. FRC were defined as documented inflammatory, infectious, migratory, or mixed manifestations temporally associated with prior filler exposure and attributed by the treating clinical team to filler injections. A total of 222 transgender women were included, with a median age of 45 years (IQR 38–52). Overall, 99 participants (44.5%) were classified as having FRC, most commonly inflammatory or mixed presentations. Materials referred to as “biopolymers” were the most frequently reported injected substances, followed by injectable oils, and among participants with available information, 93% of injections were performed by non-medical personnel. The time between filler injection and symptom onset exceeded 5 years in 54% of participants with FRC. More than one-third of affected participants required hospitalization attributable to FRC. Nearly half of transgender women with prior filler injections experienced complications, underscoring the substantial morbidity associated with filler injections performed outside supervised medical care. These findings highlight the multifactorial structural and social context surrounding non-medically supervised filler use, including barriers to gender-affirming healthcare, and the need for multidisciplinary care pathways for FRC. Because this retrospective study was conducted at referral centers, severe complications may be overrepresented.
Acknowledgements
We dedicate this work to all the participants of this study, as well as to all transgender women who have lost their lives due to complications associated with filler injections. We honor the knowledge and insight they shared during their lifetimes, from which we have learned and continue to learn.
Funding
This study did not receive specific funding.
Author information
Authors and Affiliations
Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Karen Aranza Marañón-Solorio, Alvaro López-Iñiguez, Alfredo Ponce-de-León & Fernanda González-Lara
Clínica Especializada Condesa, Mexico City, Mexico
Mariana Vélez-Pintado, América Sarahí Martínez-Frías, Esmeralda Román-Mar, Mitzi Zaira Fong-Ponce, Montserrat Staeps-Gordoa, Juanita Lastra-Torres & María Eugenia Zghaib-Rivero
Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico
Elizabeth Vancini-Nieto
Centro Nacional de Prevención y Control de Enfermedades (CENAPRECE), Mexico City, Mexico
Paula Viveros-Wacher
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No.15, Colonia Belisario Domínguez Sección XVI, Tlalpan, Mexico City, C.P. 14080, Mexico
Fernanda González-Lara
Authors
- Karen Aranza Marañón-Solorio
- Mariana Vélez-Pintado
- América Sarahí Martínez-Frías
- Esmeralda Román-Mar
- Mitzi Zaira Fong-Ponce
- Montserrat Staeps-Gordoa
- Juanita Lastra-Torres
- Elizabeth Vancini-Nieto
- María Eugenia Zghaib-Rivero
- Paula Viveros-Wacher
- Alvaro López-Iñiguez
- Alfredo Ponce-de-León
- Fernanda González-Lara
Corresponding author
Correspondence to Fernanda González-Lara.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Marañón-Solorio, K.A., Vélez-Pintado, M., Martínez-Frías, A.S. et al. Epidemiology and clinical outcomes of filler-related complications among transgender women in Mexico. Sci Rep (2026). https://doi.org/10.1038/s41598-026-75908-z
Received: 28 January 2026
Accepted: 09 October 2026
Published: 14 October 2026
DOI: https://doi.org/10.1038/s41598-026-75908-z
Keywords
来源:Nature 健康护理主题 · nature.com